Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Metastatic Triple-Negative Breast Cancer|HR+/HER2- Metastatic Breast Cancer|Metastatic Urothelial Cancer
Interventions: DRUG: Sacituzumab Govitecan-hziy
Sponsor: Gilead Sciences